Additionally, the ability of DPP4i to increase GLP-1 levels, which in turn has been shown to decrease Aβ levels and exert neuroprotective effects through the modulation of insulin signaling and GSK-3β activity, further strengthens the potential of DPP4i in AD treatment [16,18,19,21-24]. This evidence concerns the gene GSK3B and Alzheimer disease.